CaSRevolution
Private Company
Total funding raised: $2.5M
Overview
CaSRevolution is a private, preclinical-stage biotech pioneering a novel CRISPR-based gene therapy platform targeting neurodegenerative diseases. Founded in Milan in 2019, the company is developing potentially curative approaches that aim to modify disease progression, a significant unmet need in neurology. While still in early research and development, its focus on cutting-edge genetic tools positions it in a high-potential but competitive segment of the biopharma industry. The company appears to be in a foundational, pre-revenue stage, building its technology and pipeline.
Technology Platform
CRISPR-based gene editing platform combined with gene therapy delivery systems, aimed at creating disease-modifying treatments for neurological disorders.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Highly competitive. CaSRevolution competes with large-cap gene editing leaders (e.g., CRISPR Therapeutics, Intellia, Editas) and numerous neurology-focused biotechs developing gene therapies, antisense oligonucleotides, and other modalities. Differentiation will require demonstrating superior delivery, editing efficiency, or safety in the CNS.